Shinobi Therapeutics
South San Francisco
About Shinobi Therapeutics
Shinobi Therapeutics focuses on creating hypoimmune CD8╬▒╬▓ iPS-T cells that work with the immune system to treat cancer and other diseases. The company utilizes advanced immune evasion technology to enhance the effectiveness and accessibility of cell therapies. Shinobi's innovative approach aims to reduce costs and improve patient outcomes through durable responses and redosing capabilities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $178.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2024)
- Website: shinobitx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/shinobi-therapeutics-98023 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.